Market Overview

Deutsche Bank Reiterates On Medtronic And Covidien Amid Acquisition Proposal

Share:
Related MDT
Medtronic Adds New Resolute Onyx Drug-Eluting Stent Sizes, and Expands Indications
Are Share Repurchases On The Horizon?
Consider This Strategy To Reduce Stock Market Anxiety (Seeking Alpha)

In a note released Tuesday morning, Deutsche Bank analyst Kristen Stewart reiterated a Buy rating on both Medtronic (NYSE: MDT) and Covidien plc (NYSE: COV) and raised her price targets from $74.00 to $85.00 and from $93.00 to $114.00, respectively.

The change in price target comes amid a proposed acquisition of Covidien by Medtronic, which Stewart is saying has a "high likelihood" of closing.

Stewart wrote, "We believe the whole is greater than the sum-of-the-parts. Medtronic plc will be a stronger, better positioned company and a more attractive investment for investors."

In terms of synergies, Stewart noted that she believes the target cost synergy of at least $850 million is "just that (at least)" and said that, although management has not made any projections for revenue synergies, she believes there will be such synergies in both the near- and long-term.

Latest Ratings for MDT

DateFirmActionFromTo
Nov 2015Credit SuisseMaintainsOutperform
Oct 2015Evercore ISI GroupUpgradesHoldBuy
Sep 2015JefferiesMaintainsHold

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Kristen StewartAnalyst Color Price Target Reiteration M&A Analyst Ratings

 

Related Articles (COV + MDT)

Get Benzinga's Newsletters